CLEVELAND and DALLAS, April 9, 2026 – Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider Premier Biotech (“Premier” or the “Company”) has acquired GH Solutions (“GH”), a distributor of point-of-care diagnostic testing products. GH Solutions serves customers across the United States, primarily in the government and workplace end markets. This combination increases Premier’s customer base and broadens the solutions that GH can offer to its existing network. GH’s dedication to superior customer service and its long-tenured customer portfolio made it a natural fit with Premier.
“Working with Premier Biotech is an exciting next step for GH. We are looking forward to the partnership opportunity and bringing Premier Biotech’s full solution to our customer base. Premier’s oral fluid, laboratory and technology portfolio is unmatched in the industry and is expected to be game changing to our customers,” said David Link, CEO of GH Solutions.
“The acquisition marks another pivotal step in our growth journey and bolsters our leadership position across the drug and alcohol testing industry,” said Premier CEO Matt Michalik. “GH adds meaningful, long-term customers to our Government and Workplace businesses with significant cross-sell potential. We view the partnership as another key milestone in our ongoing efforts to differentiate ourselves in the market.”
Premier Biotech has completed five acquisitions since partnering with ACP in November of 2022. The Company will continue to pursue additional acquisitions and collaboration opportunities to further accelerate its growth. The ACP team of Rob Langley, Ervin Cash, Matt Bowen and Sarah Mahosky worked alongside Premier Management on the transaction.
Disclosures: This press release is not an offer to sell securities or interests in any fund managed by ACP. The statements quoted above were made by persons who are not clients of ACP and they have not received compensation for the above statements. These statements are solely their opinion and representative of their experience with ACP.